全球臨床化學和免疫檢測產業，2023-2028

Clinical Chemistry and Immunoassay Industry, Global, 2023-2028

出版日期: 2024年10月30日 | 出版商:

Frost & Sullivan | 英文 69 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

整合、可擴展的核心實驗室解決方案可推動轉型成長

該分析考察了全球臨床化學和免疫檢測領域，該領域在體外診斷 (IVD) 市場中佔據最大佔有率。這種基於實驗室的測試使用整合/獨立分析儀和各種分析/面板來支援人類健康診斷和治療，以及支援人類健康診斷和治療的其他解決方案和服務。

臨床化學設備和測試針對體液中的各種化學物質來評估患者的健康狀況和臨床管理，而免疫檢測設備和測試則利用抗體與抗原的結合來評估患者的健康狀況和臨床管理。並識別和測量特定物質。這項競爭性分析考察了提供廣泛的臨床化學和免疫檢測系統（包括設備和耗材）的 IVD 公司。典型的最終用戶包括醫院、診所、診斷實驗室和研究機構。市場收益估計和預測按癌症/腫瘤、心臟病、糖尿病、感染疾病和其他應用進行分類。根據趨勢，我們確定了四個成長機會，可以最大限度地發揮經濟潛力並維持價值。

This analysis examines the global clinical chemistry and immunoassay sector, accounting for the highest share in the in vitro diagnostics (IVD) market. This type of lab-based testing analyzes body fluids (usually blood, urine, or saliva) using integrated/standalone analyzers and a wide range of assays/panels, among other solutions and services to support the diagnosis and treatment of human health.

While clinical chemistry instruments and tests target different chemicals in body fluids to evaluate health and the clinical management of patients, immunoassay instruments and tests measure the presence or concentration of analytes in biological liquid by using the binding of antibodies to antigens to identify and measure certain substances. This competitive analysis examines IVD companies that provide a broad menu of clinical chemistry and immunoassay systems, including instruments and consumables. Key end-user verticals comprise hospitals, clinics, diagnostic laboratories, and research institutions. The sector is segmented by applications, including cancer/oncology, cardiac, diabetes, infectious, and others, for market revenue estimations and forecasts. The study also identifies four growth opportunities that build on trends, maximize the economic potential, and sustain value.

Scope and Segmentation

Scope of Analysis
Segmentation

Growth Environment: Transformation in the Clinical Chemistry and Immunoassay Sector

Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Clinical Chemistry and Immunoassay Industry